OMOLOLA AKINMADELO: Open Payments
NPI 1376188151 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$683 in 27 payments from 12 companies in 2025. Trend: 2023 $439 · 2024 $723 · 2025 $683
Food & beverage: $683
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 6 | $227 |
| ABBVIE INC. | 4 | $86 |
| Ardelyx, Inc. | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Intercept Pharmaceuticals, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Gilead Sciences, Inc. | 2 | $38 |
| PFIZER INC. | 2 | $36 |
| Celltrion USA Inc. | 1 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
Products named: DUPIXENT, IBSRELA, OCALIVA, LINZESS, ENTYVIO, XELJANZ, VEGZELMA, VOQUEZNA.
Industry payments across DC — which companies pay providers there.
